Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with progressive heart failure and at present, few disease-modifying treatments exist. NNC6019-0001 is a humanized monoclonal antibody designed to deplete amyloid fibrils that result in heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to discuss the phase II study investigating NNC6019-0001 in patients with AATR-CM.
The abstract entitled ‘NNC60190001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTRCM): rationale and study design of a phase 2, randomized, placebo controlled trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What is NNC6019-0001 and what is its mechanism of action? (0:22)
- What were the methodology and eligibility criteria of your study investigating NNC6019-0001? (1:35)
- What are the primary and secondary endpoints of the study? (2:33)
- When are results expected? (3:05)
Disclosures: Marianna Fontana is on the advisory board and a consultant for Alexion, Alnylam, Caelum, Intellia, Ionis, Jannsen, Novo Nordisk and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
ESC Congress 2023 Amsterdam: Ross Campbell, OPERA-AI trial, handheld echocardiography in suspected heart failure
Presented at the European Society of Cardiology Congress (ESC Congress) 2023 Amsterdam, the OPERA-AI trial compared the use of handheld echocardiography analysed by artificial intelligence (AI) to ‘cart-based’ echocardiography reported by humans, to help diagnose suspected heart failure. In this touchCARDIO interview, we speak to Dr. Ross Campbell (University of Glasgow, Glasgow, UK) to discuss the […]
ESC Congress 2023 Amsterdam: Robert Mentz, HEART-FID trial, intravenous iron for heart failure with reduced ejection fraction
The HEART-FID trial built on research from the AFFIRM-AHF and IRONMAN trials to investigate the use of intravenous iron in treating heart failure with iron deficiency. In this touchCARDIO interview, we speak to Dr. Robert Mentz (Duke University, NC, US) regarding the HEART-FID trial, presented at the European Society of Cardiology Congress (ESC Congress) 2023 […]
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!